Industry News
Pharmaceutical Industry News
The sketch show’s latest pharma…
The sketch show’s latest pharma ad spoof arrived during this past weekend’s episode hosted by actor Ryan Gosling, who appears in the Otezla send-up as a patient now able to shed his long sleeves after
Issues at a former Catalent plant…
Issues at a former Catalent plant now owned by Novo Nordisk have derailed another FDA application. Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line
After an independent data…
After an independent data monitoring committee raised safety flags in a clinical trial, Ipsen is shutting down the cancer med Tazverik, which it picked up through its acquisition of Epizyme less than four years ago.
Under the deal with Lone Star…
Under the deal with Lone Star Funds, Lonza maintains a 40% stake in its capsules and health ingredients business while receiving 1.7 billion Swiss francs ($2.2 billion) upfront.
Sen. Ron Wyden of Oregon is going…
Sen. Ron Wyden of Oregon is going straight to drugmakers in search of details on their "most favored nation" pricing deals with Donald Trump.
Sanofi has agreed to sell its…
Sanofi has agreed to sell its Medley generics unit in Brazil to leading local drugmaker EMS, according to an announcement from international law firm Mayer Brown. An EMS exec said the deal is valued at
Almost all of last month’s top…
Almost all of last month’s top 10 pharma TV ad spenders took advantage of February’s two major sporting events to get the word out about their meds.
The three-pronged plan to…
The three-pronged plan to strengthen domestic drug supply will be supported by an investment of 24 billion new Taiwan dollars ($755 million), President Lai Ching-te said.
Less than two weeks after Pfizer…
Less than two weeks after Pfizer struck a deal with Sciwind Biosciences to gain commercial rights to a GLP-1 drug, China's National Medical Products Administration (NMPA) has approved the treatment for patients with obesity.
Servier on Friday unveiled a deal…
Servier on Friday unveiled a deal to acquire Day One Biopharmaceuticals—a commercial-stage company developing targeted therapies for pediatric cancers and other diseases—for $21.50 per share in cash. The total value of the deal, which is
Kyowa Kirin has decided to…
Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. Sanofi is committing up to $1.5 billion for global rights to Sino Biopharm's first-in-class JAK/ROCK inhibitor.
La mayoría de los pacientes mantendrían su peso con menos dosis de medicamentos GLP-1
En una investigación reciente, un pequeño grupo de pacientes recibió las inyecciones con menos frecuencia, pero aun así mantuvo la pérdida de peso y los beneficios para la salud.
Fewer Pregnant Women Received Acetaminophen in E.R.s After White House Warnings
A new analysis of prescription data found that emergency room orders for acetaminophen for pregnant women fell for weeks after the federal warning.
F.D.A. Faces Upset Over Denials of New Drugs
Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing
As AI and automation reshape drug…
As AI and automation reshape drug discovery, laboratories themselves are being forced to evolve. Gensler’s Ryley Poblete joins the podcast to explain how new technologies, the makeup of scientific teams and new ways of collaboration
The FDA has approved the first…
The FDA has approved the first true generic version of GSK's asthma inhaler Flovent, signing off on Glenmark's fluticasone propionate inhalation aerosol. For more than two years, Prasco Laboratories has sold an "authorized generic" version
After delivering solid sales…
After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S. generics
Galderma has doubled its peak…
Galderma has doubled its peak annual sales estimate for Nemluvio (nemolizumab) to more than $4 billion, following what CEO Flemming Ørnskov described as an “outstanding launch trajectory” for the Dupixent competitor in its first full
Leo Pharma has decided “It’s…
Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. Having built its growth plans on the recently approved medicine, the Danish drugmaker is running a direct-to-consumer campaign, including
Forma Life Sciences, which…
Forma Life Sciences, which inherited BioDuro’s California operations earlier this year, officially launched as a CDMO with a focus on oral solid dosage drugs this week.